Investors Buy Large Volume of Genmab A/S Call Options (NASDAQ:GMAB)

Posted by Brian Himes on Aug 26th, 2026

Genmab A/S Sponsored ADR (NASDAQ:GMAB – Get Free Report) saw unusually large options trading on Wednesday. Traders purchased 4,002 call options on the stock. This is an increase of 169% compared to the average volume of 1,487 call options.

Genmab A/S Stock Down 2.4%

Shares of GMAB traded down $0.82 on Wednesday, reaching $33.54. The stock had a trading volume of 1,095,343 shares, compared to its average volume of 1,955,105. The company has a debt-to-equity ratio of 0.81, a quick ratio of 2.44 and a current ratio of 2.46. Genmab A/S has a 12-month low of $23.62 and a 12-month high of $35.43. The firm has a market capitalization of $20.91 billion, a price-to-earnings ratio of 26.41, a price-to-earnings-growth ratio of 1.96 and a beta of 0.83. The company has a 50-day simple moving average of $29.18 and a 200-day simple moving average of $27.94.

Genmab A/S (NASDAQ:GMAB – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.37 by $0.17. The company had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.12 billion. Genmab A/S had a return on equity of 14.89% and a net margin of 19.08%. Sell-side analysts predict that Genmab A/S will post 1.17 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Paradigm Biocapital Advisors LP purchased a new position in Genmab A/S during the 3rd quarter valued at about $117,063,000. Orbis Allan Gray Ltd lifted its holdings in shares of Genmab A/S by 30.2% during the fourth quarter. Orbis Allan Gray Ltd now owns 14,418,462 shares of the company’s stock valued at $444,089,000 after purchasing an additional 3,340,456 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its holdings in shares of Genmab A/S by 36.6% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 4,978,058 shares of the company’s stock valued at $153,324,000 after purchasing an additional 1,334,919 shares during the last quarter. First Trust Advisors LP boosted its position in shares of Genmab A/S by 84.3% in the 1st quarter. First Trust Advisors LP now owns 2,461,342 shares of the company’s stock worth $66,038,000 after purchasing an additional 1,126,069 shares in the last quarter. Finally, Pictet Asset Management Holding SA bought a new stake in shares of Genmab A/S in the 4th quarter worth approximately $33,835,000. 7.07% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on GMAB. Guggenheim lifted their price objective on Genmab A/S from $40.00 to $42.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. TD Cowen raised Genmab A/S from a “hold” rating to a “buy” rating and raised their price target for the stock from $32.00 to $43.00 in a research note on Wednesday, July 22nd. Weiss Ratings upgraded shares of Genmab A/S from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, August 11th. Truist Financial began coverage on shares of Genmab A/S in a research report on Wednesday, May 27th. They set a “buy” rating and a $40.00 price objective on the stock. Finally, HC Wainwright upped their price objective on shares of Genmab A/S from $38.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, July 2nd. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $39.50.

Get Our Latest Report on GMAB

Genmab A/S Company Profile

(Get Free Report)

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.